Aldeyra Therapeutics, Inc. (NASDAQ:ALDX – Get Free Report) Director Richard Douglas purchased 200,000 shares of the company’s stock in a transaction dated Wednesday, November 11th. The stock was purchased at an average cost of $0.64 per share, for a total transaction of $128,000.00. Following the transaction, the director owned 395,000 shares of the company’s stock, valued at approximately $252,800. This trade represents a 102.56% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Aldeyra Therapeutics Stock Performance
Shares of Aldeyra Therapeutics stock opened at $0.64 on Monday. The firm has a fifty day simple moving average of $0.97 and a 200-day simple moving average of $2.09. The stock has a market capitalization of $38.86 million, a price-to-earnings ratio of -2.01 and a beta of 1.33. Aldeyra Therapeutics, Inc. has a 1-year low of $0.53 and a 1-year high of $5.93.
Aldeyra Therapeutics (NASDAQ:ALDX – Get Free Report) last posted its earnings results on Thursday, November 5th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.05. As a group, research analysts predict that Aldeyra Therapeutics, Inc. will post -0.27 earnings per share for the current year.
Hedge Funds Weigh In On Aldeyra Therapeutics
A number of hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP raised its stake in shares of Aldeyra Therapeutics by 1.9% in the first quarter. Dimensional Fund Advisors LP now owns 624,170 shares of the biotechnology company’s stock worth $1,055,000 after acquiring an additional 11,912 shares during the last quarter. Chicago Partners Investment Group LLC acquired a new stake in shares of Aldeyra Therapeutics in the 1st quarter valued at $33,000. Hikari Power Ltd bought a new stake in shares of Aldeyra Therapeutics during the second quarter worth $43,000. Bank of New York Mellon Corp lifted its stake in shares of Aldeyra Therapeutics by 18.1% during the first quarter. Bank of New York Mellon Corp now owns 136,746 shares of the biotechnology company’s stock valued at $231,000 after acquiring an additional 20,980 shares during the period. Finally, Two Sigma Securities LLC acquired a new stake in Aldeyra Therapeutics in the second quarter worth about $70,000. Institutional investors and hedge funds own 59.71% of the company’s stock.
Analyst Upgrades and Downgrades
Several brokerages recently weighed in on ALDX. Weiss Ratings downgraded Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, September 14th. HC Wainwright reissued a “neutral” rating and issued a $2.00 price objective on shares of Aldeyra Therapeutics in a research report on Wednesday, September 30th. BTIG Research reaffirmed a “buy” rating on shares of Aldeyra Therapeutics in a research report on Tuesday, September 29th. Finally, Wall Street Zen downgraded shares of Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Aldeyra Therapeutics currently has an average rating of “Hold” and a consensus target price of $2.00.
Check Out Our Latest Stock Analysis on ALDX
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing treatments for immune-mediated diseases, including conditions affecting the eye. The company’s research centers on reactive aldehyde species (RASP), which it aims to inhibit to address inflammation and related disease processes. Aldeyra’s investigational medicines include reproxalap, a small-molecule RASP inhibitor studied for ocular conditions such as dry eye disease and allergic conjunctivitis. Its pipeline has also included candidates intended to treat systemic immune-mediated conditions.
Featured Articles
- Five stocks we like better than Aldeyra Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
